Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New combo therapy aims to control blood cancer with shorter, smarter treatment

NCT ID NCT05677919

Summary

This study is testing a combination of two oral drugs, pirtobrutinib and venetoclax, for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see if using a sensitive blood test that detects tiny amounts of leftover cancer cells can help guide how long treatment should last. The goal is to control the cancer effectively while potentially limiting the total time patients need to be on therapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

Conditions

Explore the condition pages connected to this study.